American Century Companies Inc. increased its position in shares of Biohaven Ltd. (NYSE:BHVN – Free Report) by 9.5% during ...
Xponance Inc. lifted its position in shares of Biohaven Ltd. (NYSE:BHVN – Free Report) by 25.9% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 6,148 shares of ...
In March 2024, InvestingPro’s Fair Value model identified Biohaven Ltd. (NYSE:BHVN) as significantly overvalued at $56.37. One year later, this analysis has proven remarkably accurate ...
Pre-Open Stock Movers: Biohaven Pharmaceutical (BHVN) 71% HIGHER; Pfizer Inc. (NYSE:PFE) and Biohaven Pharmaceutical Holding ...
NEW YORK, NY / ACCESS Newswire / March 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.") (NYSE:BHVN) concerning possible ...
A stock is considered to be oversold if the RSI reading falls below 30. In trading on Thursday, shares of Biohaven Ltd (Symbol: BHVN) entered into oversold territory, hitting an RSI reading of 29. ...
On Wednesday, H.C. Wainwright reaffirmed a Buy rating and a price target of $54.00 on Biohaven Pharmaceutical (TADAWUL:2070) ...
A growing cohort of biotechs, from Biohaven to Neurocrine to Jazz, hope research on ion channels will bring them new drugs and big business — much like it has done for Vertex.
Biohaven Ltd. (NYSE:BHVN) reported positive topline results in their 3-year study of troriluzole for treating spinocerebellar ataxia (SCA), demonstrating a 50% slowing in disease progression on ...
Biohaven reported Q4 earnings on March 3 and ... the primary focus for the stock to remain on upcoming FDA action on Troriluzole for Spinocerebellar Ataxia this summer. Effectively assess a ...
Biohaven’s potassium channel drug has failed a late-stage study in bipolar mania, according to a statement in the company’s fourth-quarter earnings report.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback